Viking Therapeutics, Inc. (VKTX) Stock Price & Analysis
Viking Therapeutics, Inc. (VKTX) is trading at USD 26.28, down 2.23% today, as of November 18, 2026 at 20:43 UTC (US market open; quotes may be delayed), according to Nexqual market data.
VKTX last closed at USD 26.28; today's session has ranged USD 26.26–27.36 on volume of 2,134,544 shares. Market capitalization is —, with a 52-week range of USD 23.82–43.1 (NCM). Source: Nexqual, retrieved November 18, 2026 at 20:43 UTC.
What changed for VKTX since Aug 31, 2025
The built-in knowledge of several widely used AI models ends around Aug 31, 2025. Everything below is newer, dated and sourced (as of Nov 18, 2026).
- Viking Therapeutics, Inc. (VKTX) stock went from USD 27.05 (close of the week of Aug 25, 2025, split-adjusted) to USD 26.28, a -2.8% price change; the S&P 500 (SPY) moved +14.9% over the same period.
- Analyst actions on VKTX in the last 120 days: 7 (3 upgrades or target raises, 3 downgrades or target cuts); most recent Canaccord Genuity, Oct 31, 2026.
Also available as compact Markdown for AI agents: nexqual.com/VKTX.md
Key facts (VKTX)
- Last four reported quarters (through Sep 30, 2026): revenue $0K, net income -$627M (SEC filings).
- Insider open-market sales, last ~7 months: 3 Form 4 filings, $6.3M; 3 not under a Rule 10b5-1 plan ($6.3M); 3 by opportunistic insiders (3 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Total return with dividends: 1Y -30.4% vs S&P 500 +11.9%; 5Y +366.0% vs S&P 500 +66.7%.
- Latest earnings report: 2026-10-28 (next date not yet announced).
- Dividend: VKTX paid no cash dividend in the last five years.
- Short interest: 19.93% of float (as of 2026-10-30), 4.5 days to cover.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (VKTX)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0K | $0K | $0K | $0K | $0K | $0K |
| Operating income | -$55.7M | -$70.4M | -$101M | -$151M | -$393M | -$649M |
| Net income | -$55.0M | -$68.9M | -$85.9M | -$110M | -$360M | -$627M |
| EPS (diluted) | -$0.71 | -$0.90 | -$0.91 | -$1.01 | -$3.19 | — |
| Cash + short-term investments | $202M | $155M | $362M | $903M | $706M | — |
| Total debt | — | — | — | — | $0K | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Sep 30, 2026) (VKTX)
P/B 5.8x · Earnings yield -18.51% · Net cash $709M · EV $2.68B
Insider sales (SEC Form 4, open-market, last ~7 months) (VKTX)
0 of 3 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-07-29 | Lian Brian | President & CEO | 148,517 | $4.9M | 5.5% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-07-29 | Zante Greg | Chief Financial Officer | 21,217 | $710K | 9.1% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-07-29 | Mancini Marianna | Chief Operating Officer | 18,217 | $610K | 4.1% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (VKTX)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-31 | Canaccord Genuity | Target raised | Buy | $106 → $118 |
| 2026-10-20 | Canaccord Genuity | Target lowered | Buy | $114 → $106 |
| 2026-10-15 | UBS | Initiated | Buy | $94 |
| 2026-10-07 | Truist Securities | Target lowered | Buy | $87 → $85 |
| 2026-09-23 | Truist Securities | Target raised | Buy | $83 → $87 |
| 2026-08-11 | JP Morgan | Target lowered | Overweight | $75 → $65 |
| 2026-07-30 | Canaccord Genuity | Target raised | Buy | $107 → $114 |
Total return (dividends reinvested) (VKTX)
| 1Y (from 2025-11-18) | 5Y (from 2021-11-15) | |
|---|---|---|
| Total return | -30.4% | +366.0% |
| S&P 500 (SPY) | +11.9% | +66.7% |
| Per year | -30.4% | +36.0% |
| Volatility (annualized) | 67.2% | 91.7% |
| Max drawdown | -42.5% (Jul 2026→Oct 2026) | -73.9% (Feb 2024→Apr 2025) |
Dividends (VKTX)
VKTX paid no cash dividend in the last five years.
Short interest (VKTX)
24,163,022 shares sold short, 19.93% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 25,921,759 shares (-6.8%). Days to cover: 4.5 (short shares ÷ average daily volume).
VKTX earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Oct 28, 2026 | Quarter ended Sep 30, 2026 | −$1.55 | −$1.06 | Miss −46.2% | +7.9% |
| Jul 29, 2026 | Quarter ended Jun 30, 2026 | −$1.10 | −$1.21 | Beat +9.1% | -2.2% |
| Apr 29, 2026 | Quarter ended Mar 31, 2026 | −$1.37 | −$0.91 | Miss −50.5% | -3.7% |
| Feb 11, 2026 | Quarter ended Dec 31, 2025 | −$1.38 | −$0.90 | Miss −53.3% | +6.1% |
| Oct 22, 2025 | — | — | — | — | +2.9% |
| Jul 23, 2025 | — | — | — | — | +4.4% |
| Apr 23, 2025 | — | — | — | — | +0.7% |
| Feb 5, 2025 | — | — | — | — | -2.8% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
VKTX recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Nov 5, 2026 | Schedule 13G/A | FMR LLC, Abigail P. Johnson: 7.7% of shares, passive 5%+ holder (amended) |
| Oct 29, 2026 | 10-Q | Quarterly report · period ended Sep 30, 2026 |
| Oct 28, 2026 | 8-K | Quarterly results |
| Sep 28, 2026 | 8-K | Entered a material agreement; New debt or off-balance-sheet obligation “Equity Offering On September 23, 2026, Viking Therapeutics, Inc. (the "Company") entered into an underwriting agreement (the "Equity Underwriting Agreement") with Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC (the "Equity Representatives"), as representatives of the several underwriters named therein (the "Equity Underwriters"), to issue and sell (the "Equity Offering") 7,857,143 shares of the Company's common stock, par value $0.00001 per share ("Common Stock"), at a public offering price of $35.00 per…” |
| Sep 22, 2026 | 8-K | Other material event “On September 22, 2026, Viking Therapeutics, Inc. issued a press release announcing top-line results from its maintenance study of GLP-1/GIP agonist VK2735. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.” |
| Jul 29, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Jul 29, 2026 | 8-K | Quarterly results |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
VKTX suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | LIGAND PHARMACEUTICALS INC (LGND) | “We obtained exclusive worldwide rights to VK2809, VK0214 and VK5211 and certain other assets pursuant to an exclusive license agreement with Ligand Pharmaceuticals Incorporated, or Ligand.” |
| Competitor | Novo Nordisk (NVO) | “VK2735, if approved, will compete against therapies that are already approved and marketed for obesity, including Semaglutide (Wegovy®) and liraglutide (Saxenda®) from Novo Nordisk A/S, and tirzepatide (Zepbound®) from Eli Lilly and Company.” |
| Competitor | Eli Lilly (LLY) | “VK2735, if approved, will compete against therapies that are already approved and marketed for obesity, including Semaglutide (Wegovy®) and liraglutide (Saxenda®) from Novo Nordisk A/S, and tirzepatide (Zepbound®) from Eli Lilly and Company.” |
Quoted from the company's 10-K filed Feb 11, 2026.
VKTX company outlook (results filed Oct 28, 2026)
- “Upon completion, we expect to initiate a 28-day multiple ascending dose study of VK3019 in the first quarter of 2027.”
- “The company expects these studies to be completed in 2027. • VANQUISH Extension Studies to Commence in 1Q27.”
- “The company anticipates the results of the extension studies to be available in 2028. • SUNRISE Oral Phase 3 VK2735 Program Initiated;”
- “Importantly, results from this study will help inform the selection of doses in the upcoming VANQUISH extension studies, expected to begin in early 2027. • Part 2 Maintenance Dosing Study Initiated, to Evaluate Oral and Additional Subcutaneous Regimens.”
Quoted word-for-word from the SEC 8-K results press release.
VKTX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Dec 2026) | $-1.35 | $-1.10 | −$0.25 | $0 | 18 |
| Next quarter (ends Mar 2027) | $-1.36 | $-1.05 | −$0.31 | $0 | 7 |
| Current fiscal year (ends Dec 2026) | $-5.31 | $-4.61 | −$0.71 | $0 | 18 |
| Next fiscal year (ends Dec 2027) | $-5.21 | $-4.32 | −$0.89 | $0 | 18 |
VKTX options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 2 | 123.5% | ±7.4% |
| Nov 27, 2026 | 9 | 57.9% | ±7.9% |
| Dec 4, 2026 | 16 | 88.4% | ±14.9% |
| Dec 11, 2026 | 23 | 82.9% | ±16.7% |
| Dec 18, 2026 | 30 | 64.0% | ±15.1% |
| Dec 24, 2026 | 36 | 45.1% | ±11.4% |
| Dec 31, 2026 | 43 | 56.5% | ±15.6% |
| Jan 15, 2027 | 58 | 64.3% | ±20.8% |
30-day implied volatility 65.2% vs 74.9% realized over the last 30 trading days. Put/call ratio (volume) 0.68. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of November 18, 2026 at 20:43 UTC)
| Price | USD 26.28 |
|---|---|
| Change | ▼ 2.23% (down) |
| Previous Close | USD 26.28 |
| Open | USD 26.28 |
| Day Range | USD 26.26 – 27.36 |
| 52-Week Range | USD 23.82 – 43.1 |
| Volume | 2,134,544 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (VKTX)
Nexqual's technical model rates VKTX "SELL" based on 1 bullish and 5 bearish signals across 129 daily candles, as of November 18, 2026 at 20:43 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 44.49 (neutral) |
| vs SMA50 | Below (USD 28.9) |
| MACD | -0.27 (negative) |
Earnings (VKTX)
| Next Earnings Date | 2026-10-28 |
|---|---|
| EPS Estimate | USD -1.35 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-09-30 | USD -1.55 vs est -1.06 ▼ miss |
| 2026-06-30 | USD -1.1 vs est -1.21 ▲ beat |
| 2026-03-31 | USD -1.37 vs est -0.91 ▼ miss |
| 2025-12-31 | USD -1.38 vs est -0.9 ▼ miss |
Source: Nexqual, November 18, 2026 at 20:43 UTC.
Financials & Fundamentals (VKTX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -96.37% |
| Debt / Equity | 0.43 |
| Current Ratio | 7.27 |
| Total Cash | $959.81M |
| Total Debt | $254.69M |
Source: Nexqual, November 18, 2026 at 20:43 UTC.
Financial Health Score (VKTX)
Nexqual rates Viking Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of November 18, 2026 at 20:43 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $960M cash and investments vs $251M debt (Sep 2026, SEC), net cash |
| Cash Flow | Weak — Operating cash flow -$279M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -107%, ROA -64.2% (last 4 quarters, SEC) |
Ownership (VKTX)
| Insider Ownership | +2.83% |
|---|---|
| Institutional Ownership | +64.06% |
| Shares Outstanding | 127.52M |
| Float | 124.60M |
| Short % of Float | +19.93% |
Source: Nexqual, November 18, 2026 at 20:43 UTC.
From Viking Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-11)
Partnerships
- We obtained exclusive worldwide rights to VK2809, VK0214 and VK5211 and certain other assets pursuant to an exclusive license agreement with Ligand Pharmaceuticals Incorporated, or Ligand.
Legal & Regulatory Risks (Item 1A, quoted)
- Our drug candidates may cause undesirable side effects that could delay or prevent their regulatory approval or commercialization or have other significant adverse implications on our business, financial condition and results of operations.
- Our drug candidates are subject to extensive regulation under the FDA, EMA or comparable foreign authorities, which can be costly and time consuming, cause unanticipated delays or prevent the receipt of the required approvals to commercialize our drug candidates.
- We and our contract manufacturers are subject to significant regulation with respect to manufacturing our drug candidates. The manufacturing facilities on which we rely may not continue to meet regulatory requirements.
- We are subject to "fraud and abuse" and similar laws and regulations, and a failure to comply with such regulations or prevail in any litigation related to noncompliance could harm our business, financial condition and results of operations.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MDGL | Madrigal Pharmaceuticals, Inc. | USD 397.1 | ▼ 5.9% |
| SMMT | Summit Therapeutics Inc. | USD 10.53 | ▼ 1.36% |
| TGTX | TG Therapeutics, Inc. | USD 66.18 | ▲ 5.53% |
| KOD | Kodiak Sciences Inc | USD 98.14 | ▲ 1.38% |
| BLTE | Belite Bio, Inc | USD 157.14 | ▼ 0.37% |
| ORKA | Oruka Therapeutics, Inc. | USD 95.92 | ▼ 0.42% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 20:43 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt